FDA Issues Warnings to Online Retailers for Selling Unauthorized E-cigarette Products

Aug.24.2023
FDA Issues Warnings to Online Retailers for Selling Unauthorized E-cigarette Products
FDA Warns Online Retailers for Selling Unauthorized E-cigarette Products with Child Attractive Packaging Designs.

On August 23rd, the Food and Drug Administration (FDA) issued warning letters to 15 online retailers for the sale and/or distribution of unauthorized e-cigarette products. The packaging designs of these products appeared to be targeting children, resembling characters, educational materials, toys, and beverages.


The FDA also stated that, considering the deceiving appearance of these illicit products, they are also planning to caution parents, teachers, and other adults to remain vigilant before the start of the new school year.


Dr. Brian King, director of the FDA's Center for Tobacco Products (CTP), stated


The design of these products shamelessly aims to attract children, even though adults use e-cigarettes to quit smoking, they don't need them to look like SpongeBob SquarePants in order to be successful.


The unauthorized products described in the warning letter include:


Featuring popular characters that captivate children in TV shows, movies, and video games, including "SpongeBob SquarePants," "Care Bears," and "Mario.


Designed to resemble learning tools that appeal to children, such as highlighter pens, and toys like Nintendo Game Boy and digital cameras; imitating beverages that attract children, like Starbucks and Dunkin' Donuts' coffee cups, soda cans, and water bottles.


The FDA states that the retailers who received these warning letters have been selling and/or distributing e-cigarette products in the United States without FDA authorization, which is a violation of the Federal Food, Drug, and Cosmetic Act's requirement for legally selling new tobacco products.


In addition to the specified products mentioned in the warning letter, these retailers have also been cautioned to address any similar violations to those described in the warning letter and promptly take any necessary actions to ensure that their tobacco products sold in the United States comply with the Federal Food, Drug, and Cosmetic Act.


These retailers have been asked to respond within 15 working days, outlining the measures they will take to rectify the violations and prevent future non-compliance. If the violations are not promptly addressed, the FDA may take further action, such as imposing bans, sealing premises, and/or imposing civil fines.


The following is a list of retailers who were recently issued warning letters:


Dr. Ann Simoneau, Director of FDA Compliance and Enforcement Office, stated:


As usual, we will hold responsible anyone involved in the sale of unauthorized tobacco products that are designed with promotions, advertisements, and/or encourage the use by our country's youth.


As of August 2023, the FDA has issued warning letters to approximately 600 companies for manufacturing and/or distributing illegal tobacco products, including e-cigarette products. It has also filed civil penalty complaints against 26 e-cigarette manufacturers and is collaborating with the Department of Justice to seek injunctions against six e-cigarette manufacturers.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

2Firsts Observation|VELO at Stockholm Arlanda: Travel-Centric Messaging and Full-Line Flavour Presentation
2Firsts Observation|VELO at Stockholm Arlanda: Travel-Centric Messaging and Full-Line Flavour Presentation
2Firsts observed at Stockholm Arlanda Airport that British American Tobacco’s VELO positions the airport environment as a core marketing scenario, deploying large-format LED displays, a full flavour matrix, and clear nicotine-strength segmentation. The brand also features an instructional “How to Use VELO” section and multi-pack sales strategy, showcasing its systematic merchandising capabilities in the Nordic travel-retail channel.
Nov.19 by 2FIRSTS.ai
2Firsts Monitor | FOGER website flags customs & tariff delays; some products out of stock
2Firsts Monitor | FOGER website flags customs & tariff delays; some products out of stock
2Firsts observed on FOGER’s online retail site “FOGER VAPES” that the platform indicates restocking delays due to customs and tariff factors. Several items show limited availability or “sold out” status, with a restock alert feature offered. A previous article on the site also referenced potential tariff changes that may affect pricing.
Nov.05
2Firsts Research: VUSE Ultra Promotion in Germany, Free E-Cigarette Kit Worth €24 with Registration
2Firsts Research: VUSE Ultra Promotion in Germany, Free E-Cigarette Kit Worth €24 with Registration
2Firsts discovered during its research in Cologne, Germany, that BAT’s VUSE Ultra is running a promotional campaign. Consumers who register on the VUSE website and enter a dealer code can receive a free e-cigarette kit (including device and pods) worth €24.
Sep.23 by 2FIRSTS.ai
Italian anti-trust agency investigates PMI's marketing of smoke-free products, company denies wrongdoing
Italian anti-trust agency investigates PMI's marketing of smoke-free products, company denies wrongdoing
Italian anti-trust agency investigates Philip Morris International's promotion of smoke-free products, questioning potentially misleading language.
Oct.16 by 2FIRSTS.ai
ceshi1111
ceshi1111
Trusted by industry leaders and innovators, ARAC brings unmatched expertise in Modules 5 & 6, including label and claim development, comprehension testing, human factors/usability, and clinical-behavioral research such as actual use and switching studies. These studies generate the robust, real-world evidence needed to evaluate whether products are “Appropriate for the Protection of Public Health” (APPH) -- including randomized experimental longitudinal, actual use, cohort st
Oct.21
Altria Director George Muñoz to Retire After 2026 Shareholder Meeting;
Altria Director George Muñoz to Retire After 2026 Shareholder Meeting;
Altria director George Muñoz plans to retire post-2026 annual meeting, not seeking re-election. Annual meeting expected on May 14.
Oct.15 by 2FIRSTS.ai